Abstract
Abstract BACKGROUND Dual agent immunotherapy (dIT) has revolutionized the treatment of advanced melanoma, with recent clinical trials demonstrating its effectiveness in managing small, asymptomatic melanoma brain metastases (MBM) in the upfront setting. However, its potential role in preventing MBM has not been thoroughly investigated. MATERIAL AND METHODS A retrospective analysis was performed on the TriNetX database, which compiles clinical data from 92 healthcare organizations. Melanoma patients without MBM at diagnosis were divided into two groups: those who received ipilimumab alone (single immunotherapy, sIT) and those who received ipilimumab and nivolumab (dIT). The study compared the frequency of new asynchronous MBM diagnosis among the cohorts and analyzed the median overall survival (OS) of MBM patients using Kaplan Meier analysis and log-rank tests. Additionally, a retrospective cohort validation study was conducted on a sample of randomly selected patients treated at a single institution between 2012-2019. Electronic medical records were reviewed for demographics, melanoma treatment history, and clinical outcomes. RESULTS TriNetX identified a total of 732,555 melanoma patients, including 717,408 who did not receive immunotherapy (no-IT), 4,585 who received dual immunotherapy (dIT), and 4,101 who received single immunotherapy (sIT). The mean ages at melanoma brain metastases (MBM) diagnosis were 66.9, 61.5, and 63.2 years for each respective group. The prevalence of MBM was 1.5%, 9.6%, and 15.6% for no-IT, dIT, and sIT groups, respectively (p < 0.0001). DIT was associated with a lower rate of MBM compared to sIT(OR [95%CI], 0.64 [0.61-0.77]). After propensity score matching, the median overall survival for MBM patients was not statistically different between the no-IT, dIT, and sIT groups (347, 400, 414 days, respectively). In the validation group of 90 patients (30 no-IT, 27 sIT, 34 dIT), predominantly male (61.5%), stage III (62.5%), the prevalence of MBM was 13.8%, 59%, and 38.2% for each respective group for developing MBM (OR [95%CI], 2.35 [0.84-6.60], p=0.08). The mean time between immunotherapy initiation and MBM was 305 days for dIT and 500 days for sIT for patients who developed MBM. CONCLUSION The results suggest that using a combination of ipilimumab and nivolumab immunotherapy could be effective in reducing the incidence of brain metastases in advanced melanoma patients. Further investigation is needed to explore the potential preventive role of dIT in MBM development in this patient population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.